Another agent, osmotin, an adiponectin homolog that modulates the phosphorylation of 5′ adenosine monophosphate-activated protein kinase (AMPK) through the adiponectin receptor 1 (AdipoR1), has been found to exert neuroprotective properties in preclinical models of PD. This evidence concerns the gene ADIPOR1 and Parkinson disease.